carlos-muza-hpjsku2uysu-unsplash_1

Cognizant and Boehringer Ingelheim collaborate on integrated cloud platform to improve therapy development

April 12, 2023
Medical Communications

US-based Cognizant and biopharmaceutical company Boehringer Ingelheim have announced a partnership to collaborate on ensuring the quality, and increasing the …

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

April 11, 2023
Business Services

CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 11, 2023 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), the essential life science …

christina-victoria-craft-zhys6xn7sue-unsplash_5

Molecular Templates announces hold for phase 1 study

April 11, 2023
Research and Development

Molecular Templates has announced that the FDA has placed a partial hold on its phase 1 study for MT-0169 based …

FDA authorises marketing of MISHA Knee System for patients with knee osteoarthritis

April 11, 2023
Medical Communications

Medical device company, Moximed, has announced that the FDA granted marketing authorisation of its MISHA Knee System, an implantable shock …

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

April 11, 2023
Business Services

LONDON and RALEIGH, N.C., April 11, 2023 – Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage …

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

April 11, 2023
Business Services

Leiden, The Netherlands, April 11, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the first commercial …

Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study

April 6, 2023
Business Services

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening …

christina-victoria-craft-whsnkiwwpec-unsplash_4

AstraZeneca’s Lynparza approved by NHS England

April 6, 2023
Medical Communications

NHS England has approved the use of AstraZeneca’s Lynparza (olaparib) for the treatment of patients with breast cancer and prostate …

chuttersnap-oijvdm3zx4i-unsplash

Synapse receives FDA approval for its NeuRx DPS to treat patients with stable SCI

April 6, 2023
Research and Development

Synapse Biomedical has announced that it has gained premarket approval (PMA) from the FDA for its NeuRxDiaphragm Pacing System (NeuRx …

Innova Care Concepts expand their support to the medical negligence sector with the acquisition of Nurture Group Ltd.

April 5, 2023
Business Services

Press Release, Wednesday 5th April 2023, London… As part of a long-term strategy to increase its home adaptation services across …

Ipsen’s response to NICE’s decision on Cabometyx® (cabozantinib) for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine

April 5, 2023
Business Services

  SLOUGH, UK, 5th April 2023 – Ipsen is disappointed that the National Institute for Health and Care Excellence (NICE) …

Syncona Appoints Roel Bulthuis as Managing Partner

April 5, 2023
Business Services

05 April 2023   Syncona Ltd, a leading healthcare company focused on creating, building and scaling global leaders in life …

First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study

April 5, 2023
Business Services

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the …

BenevolentAI announces top-line Phase IIa results for its topical pan-Trk inhibitor BEN-2293 (1%) in mild-to-moderate atopic dermatitis

April 5, 2023
Business Services

London, UK, 5 April 2023: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI) announces top-line results from its Phase IIa, …

AstraZeneca reports positive results of drug combination in late-stage ovarian cancer trial

April 5, 2023
Medical Communications

AstraZeneca has announced positive high-level results from an interim analysis of the DUO-O phase 3 trial assessing a combination of …

hal-gatewood-ipl3q-gegzy-unsplash_2

FDA requires prepaid mail-back envelopes for opioid analgesics

April 5, 2023
Medical Communications

The FDA has announced that it will require opioid analgesic manufacturers to provide prepaid mail-back envelopes in outpatient pharmacies and …

Phlo acquires Truepill UK in landmark digital pharmacy consolidation

April 4, 2023
Business Services

Glasgow, UK. Phlo Technologies UK digital pharmacy leaders, have today announced their acquisition of the UK arm of US-based healthcare …

Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO

April 4, 2023
Business Services

Cambridge, UK, 04 April 2023 – Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company dedicated to resolving …

Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer

April 4, 2023
Business Services

Global contract development and manufacturing organisation (CDMO) Recipharm, has announced the appointment of Joaquim Mascaro as Chief Financial Officer.

optibrium_appointment

Optibrium Appoints Computational Modelling Expert, Dr Hamed Tabatabaei Ghomi as Head of Research

April 4, 2023
Business Services

Appointment will lead research strategy to apply the latest scientific innovations to Optibrium’s computational and AI drug discovery technologies Hamed …

The Gateway to Local Adoption Series

Latest content